Positive Efficacy And Tolerability Study Of Repatha® (evolocumab) In Statin-Intolerant Patients Published In Journal of the American Medical Association Read more about Positive Efficacy And Tolerability Study Of Repatha® (evolocumab) In Statin-Intolerant Patients Published In Journal of the American Medical Association
Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide Read more about Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide
Amgen To Present Repatha® (Evolocumab) Data At ACC.16 Read more about Amgen To Present Repatha® (Evolocumab) Data At ACC.16
Amgen And UCB Announce Positive Top-Line Results From Phase 3 Study Evaluating Romosozumab In Men With Osteoporosis Read more about Amgen And UCB Announce Positive Top-Line Results From Phase 3 Study Evaluating Romosozumab In Men With Osteoporosis
Amgen Wins Patent Case On Repatha® (Evolocumab) Read more about Amgen Wins Patent Case On Repatha® (Evolocumab)
FDA Accepts Amgen's Supplemental Biologics License Application For The Expanded Use Of Enbrel® (Etanercept) To Treat Pediatric Patients With Chronic Severe Plaque Psoriasis Read more about FDA Accepts Amgen's Supplemental Biologics License Application For The Expanded Use Of Enbrel® (Etanercept) To Treat Pediatric Patients With Chronic Severe Plaque Psoriasis
Amgen To Present At The Cowen And Company 36th Annual Health Care Conference Read more about Amgen To Present At The Cowen And Company 36th Annual Health Care Conference
Amgen Announces 2016 Second Quarter Dividend Read more about Amgen Announces 2016 Second Quarter Dividend
Amgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab) Read more about Amgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab)
Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis Read more about Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis
